Gene Therapy in Retinal Dystrophies
Open accessThe DOI matches its Crossref record; 187 of the 188 references it cites were found in a registry or an index.
Abstract
Inherited retinal dystrophies (IRDs) are a group of clinically and genetically heterogeneous degenerative disorders. To date, mutations have been associated with IRDs in over 270 disease genes, but molecular diagnosis still remains elusive in about a third of cases. The methodologic developments in genome sequencing techniques that we have witnessed in this last decade have represented a turning point not only in diagnosis and prognosis but, above all, in the identification of new therapeutic perspectives. The discovery of new disease genes and pathogenetic mechanisms underlying IRDs has laid the groundwork for gene therapy approaches. Several clinical trials are ongoing, and the recent approval of Luxturna, the first gene therapy product for Leber congenital amaurosis, marks the beginning of a new era. Due to its anatomical and functional characteristics, the retina is the organ of choice for gene therapy, although there are quite a few difficulties in the translational approaches from preclinical models to humans. In the first part of this review, an overview of the current knowledge on methodological issues and future perspectives of gene therapy applied to IRDs is discussed; in the second part, the state of the art of clinical trials on the gene therapy approach in IRDs is illustrated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In most clinical retinal gene therapy studies, the vector of choice is the rAAV gene expression vector [14].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
TOLENTINO, M. J., BRUCKER, A. J., FOSNOT, J., YING, G.-S., WU, I.-H., MALIK, G., WAN, S., & REICH, S. J. (2004) · RETINA · doi:10.1097/00006982-200402000-00018 · Cited by 172
RetractedTolentino, M. J., Brucker, A. J., Fosnot, J., Ying, G.-S., Wu, I.-H., Malik, G., Wan, S., & Reich, S. J. (2004) · Retina · doi:10.1097/00006982-200408000-00039 · Cited by 31
RetractedDuplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
RNA interference is mediated by 21- and 22-nucleotide RNAs
Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,310
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299 · cited 12×
“The limit of HDR is that it occurs much less frequently than NHEJ in the S and G2 phases of cell division.”
InfluentialSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 2×
“Indeed, RPE65-LCA clinical trials were initiated in 2007 by groups from the United Kingdom and the United States [83,160,161] following the encouraging results of animal studies.”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 2×
“Indeed, RPE65-LCA clinical trials were initiated in 2007 by groups from the United Kingdom and the United States [83,160,161] following the encouraging results of animal studies.”
BackgroundKetting, R. F., Fischer, S. E. J., Bernstein, E., Sijen, T., Hannon, G. J., & Plasterk, R. H. A. (2001) · Genes & Development · doi:10.1101/gad.927801 · Cited by 1,852
Yang, H., Wang, H., Shivalila, C. S., Cheng, A. W., Shi, L., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.08.022 · Cited by 1,596
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Allikmets, R., Singh, N., Sun, H., Shroyer, N. F., Hutchinson, A., Chidambaram, A., Gerrard, B., Baird, L., Stauffer, D., Peiffer, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0397-236 · Cited by 1,435 · cited 1×
“Stargardt disease is the most common hereditary macular dystrophy caused by recessive mutations in the ABCA4 gene [179].”
BackgroundInsight into Cellular Uptake and Intracellular Trafficking of Nanoparticles
Foroozandeh, P., & Aziz, A. A. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2728-6 · Cited by 1,377
Schwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327 · cited 1×
“No immune response-adverse effects were observed and three out of seven enrolled patients experienced increased visual acuity during the 12 month trial period [182].”
BackgroundIn vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Electroporation and RNA interference in the rodent retina in vivo and in vitro
Matsuda, T., & Cepko, C. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235688100 · Cited by 1,029
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
Hamel, C. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-40 · Cited by 962
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954 · cited 2×
“Indeed, RPE65-LCA clinical trials were initiated in 2007 by groups from the United Kingdom and the United States [83,160,161] following the encouraging results of animal studies.”
BackgroundGenome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat
D'Cruz, P. M. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.4.645 · Cited by 873
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796 · cited 2×
“The AAV2-CHM virus was delivered in normal sighted mice and zebrafish, and the CHM gene was also induced in pluripotent stem cells (iPSCs) from patients with choroideremia with no evident toxicity [49,50], thus encouraging in vivo subretinal injection of the native AAV2-hCHM gene, which was reported to be safe and eff…”
InfluentialFerrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · cited 1×
“The long-term sustained effects on safety and efficacy of AAV2-RPE65 gene delivery in biallelic RPE65-mediated LCA were assessed over a period of three years with the initial improvements in visual function peaking at 6–12 months after injection [163,164].”
BackgroundGenome-editing Technologies for Gene and Cell Therapy
Maeder, M. L., & Gersbach, C. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.10 · Cited by 719
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707
GENE THERAPY: Twenty-First Century Medicine
Verma, I. M., & Weitzman, M. D. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.050304.091637 · Cited by 616
Correction of a genetic disease in mouse via use of CRISPR-Cas9
Wu, Y., Liang, D., Wang, Y., Bai, M., Tang, W., Bao, S., Yan, Z., Li, D., & Li, J. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.10.016 · Cited by 614
Towards safe, non-viral therapeutic gene expression in humans
Glover, D. J., Lipps, H. J., & Jans, D. A. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1577 · Cited by 598
Fisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547
Cunha-Vaz, J., Bernardes, R., & Lobo, C. (2011) · European Journal of Ophthalmology · doi:10.5301/ejo.2010.6049 · Cited by 539
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460 · cited 1×
“Efficient and sustained transgenic expression was demonstrated in vivo using non-integral lentiviral vectors in post-mitotic tissues, such as RPE, and at levels equivalent to those of their competent counterparts for integration [40].”
BackgroundMüller, O. J., Kaul, F., Weitzman, M. D., Pasqualini, R., Arap, W., Kleinschmidt, J. A., & Trepel, M. (2003) · Nature Biotechnology · doi:10.1038/nbt856 · Cited by 410
Lewin, A. S., Drenser, K. A., Hauswirth, W. W., Nishikawa, S., Yasumura, D., Flannery, J. G., & LaVail, M. M. (1998) · Nature Medicine · doi:10.1038/nm0898-967 · Cited by 407
Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options
Tanna, P., Strauss, R. W., Fujinami, K., & Michaelides, M. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-308823 · Cited by 370
Thomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358
The primate fovea: Structure, function and development
Bringmann, A., Syrbe, S., Görner, K., Kacza, J., Francke, M., Wiedemann, P., & Reichenbach, A. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.006 · Cited by 352
X-linked juvenile retinoschisis: Clinical diagnosis, genetic analysis, and molecular mechanisms
Molday, R. S., Kellner, U., & Weber, B. H. F. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.12.002 · Cited by 331
Testa, F., Maguire, A. M., Rossi, S., Pierce, E. A., Melillo, P., Marshall, K., Banfi, S., Surace, E. M., Sun, J., Acerra, C., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.048 · Cited by 330
Maresca, M., Lin, V. G., Guo, N., & Yang, Y. (2013) · Genome Research · doi:10.1101/gr.145441.112 · Cited by 309
Ali, R. R., Sarra, G.-M., Stephens, C., Alwis, M. D., Bainbridge, J. W. B., Munro, P. M., Fauser, S., Reichel, M. B., Kinnon, C., Hunt, D. M., et al. (2000) · Nature Genetics · doi:10.1038/77068 · Cited by 304
Gold Nanoparticles: Recent Advances in the Biomedical Applications
Zhang, X. (2015) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-015-0529-4 · Cited by 299
Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292 · cited 1×
“The subretinal injection of an AAV2/5 vector carrying Abca4 led to a reduction in the lipofuscin content and to an improvement in the retinal morphology and function for up to 5 months [109].”
BackgroundCorrection of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk
Vollrath, D., Feng, W., Duncan, J. L., Yasumura, D., D'Cruz, P. M., Chappelow, A., Matthes, M. T., Kay, M. A., & LaVail, M. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221364198 · Cited by 290 · cited 2×
“The first experiments using recombinant adenoviruses to release the MERTK gene subretinally showed functional recovery of phagocytosis and a temporary delay in photoreceptor degeneration [22].”
BackgroundThe Structure, Function and Application of the Hammerhead Ribozyme
Birikh, K. R., Heaton, P. A., & Eckstein, F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-3-00001.x · Cited by 276
Cukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268 · cited 1×
“Two phase I/II trials by intravitreal RS1 delivery have been initiated with different constructs, AAV8-scRS/IRBPhRS in adults (NCT02317887), which have already reported encouraging initial findings [187], and rAAV2tYF-CBhRS1 in children up to 6 years old (NCT02416622).”
ResultSelf-citationBennicelli, J., Wright, J. F., Komaromy, A., Jacobs, J. B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T. S., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300389 · Cited by 267 · cited 11×
“Among these genes, the RPE65 gene, expressed in RPE cells, encodes a 65 kDa specific protein that catalyzes the conversion of all-trans retinyl esters to 11-cis retinal [156].”
ResultInfluentialBeltran, W. A., Cideciyan, A. V., Lewin, A. S., Iwabe, S., Khanna, H., Sumaroka, A., Chiodo, V. A., Fajardo, D. S., Román, A. J., Deng, W.-T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118847109 · Cited by 260
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2017.04.005 · Cited by 260
Adenovirus-Based Expression Vectors and Recombinant Vaccines
Graham, F. L., & Prevec, L. (1992) · Vaccines · doi:10.1016/b978-0-7506-9265-6.50022-1 · Cited by 248
Mori, S., Wang, L., Takeuchi, T., & Kanda, T. (2004) · Virology · doi:10.1016/j.virol.2004.10.012 · Cited by 245
Kafri, T., Morgan, D., Krahl, T., Sarvetnick, N., Sherman, L., & Verma, I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11377 · Cited by 244
Mori, K., Gehlbach, P. L., Yamamoto, S., Duh, E. J., Zack, D. J., Li, Q., Berns, K. I., Raisler, B. J., Hauswirth, W. W., & Campochiaro, P. A. (2002) · PubMed · Cited by 231
Song, L. Y., Ahkong, Q. F., Rong, Q., Wang, Z., Ansell, S., Hope, M. J., & Mui, B. (2002) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00399-6 · Cited by 228
Pang, J., Chang, B., Hawes, N. L., Hurd, R. E., Davisson, M. T., Li, J., Noorwez, S. M., Malhotra, R., McDowell, J. H., Kaushal, S., et al. (2005) · PubMed · Cited by 227
Cideciyan, A. V., Jacobson, S. G., Drack, A. V., Ho, A. C., Charng, J., Garafalo, A. V., Roman, A. J., Sumaroka, A., Han, I. C., Hochstedler, M. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0295-0 · Cited by 222
Kong, J., Kim, S.-R., Binley, K., Pata, I., Doi, K., Mannik, J., Zernant-Rajang, J., Kan, O., Iqball, S., Naylor, S., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.78 · Cited by 215
Farrar, G. J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.5.857 · Cited by 203
Pang, J.-J., Chang, B., Kumar, A., Nusinowitz, S., Noorwez, S. M., Li, J., Rani, A., Foster, T. C., Chiodo, V. A., Doyle, T., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.001 · Cited by 199
Visual Acuity after Retinal Gene Therapy for Choroideremia
Edwards, T. L., Jolly, J. K., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Black, G. C., Webster, A. R., Lotery, A. J., Holder, G. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509501 · Cited by 195
Zeng, Y., Takada, Y., Kjellstrom, S., Hiriyanna, K., Tanikawa, A., Wawrousek, E., Smaoui, N., Caruso, R., Bush, R. A., & Sieving, P. A. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0576 · Cited by 191
In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector.
Li, T., Adamian, M., Roof, D. J., Berson, E. L., Dryja, T. P., Roessler, B. J., & Davidson, B. L. (1994) · PubMed · Cited by 189
Vitreous: A Barrier to Nonviral Ocular Gene Therapy
Peeters, L., Sanders, N. N., Braeckmans, K., Boussery, K., Van de Voorde, J., De Smedt, S. C., & Demeester, J. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0165 · Cited by 189 · cited 3×
“Furthermore, liposomes present some specific limitations, such as the tendency to aggregate following administration as well as retinal toxicity [103].”
BackgroundOusterout, D. G., Perez-Pinera, P., Thakore, P. I., Kabadi, A. M., Brown, M. T., Qin, X., Fedrigo, O., Mouly, V., Tremblay, J. P., & Gersbach, C. A. (2013) · Molecular Therapy · doi:10.1038/mt.2013.111 · Cited by 181
Prud'homme, G., Glinka, Y., Khan, A., & Draghia-Akli, R. (2006) · Current Gene Therapy · doi:10.2174/156652306776359504 · Cited by 175
Min, S. H., Molday, L. L., Seeliger, M. W., Dinculescu, A., Timmers, A. M., Janssen, A., Tonagel, F., Tanimoto, N., Weber, B. H. F., Molday, R. S., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.06.002 · Cited by 174
RNA Interference–Mediated Suppression and Replacement of Human Rhodopsin In Vivo
O’Reilly, M., Palfi, A., Chadderton, N., Millington-Ward, S., Ader, M., Cronin, T., Tuohy, T., Auricchio, A., Hildinger, M., Tivnan, A., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519025 · Cited by 173
Rabinowitz, J. E., Bowles, D. E., Faust, S. M., Ledford, J. G., Cunningham, S. E., & Samulski, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4421-4432.2004 · Cited by 171
Dulla, K., Aguila, M., Lane, A., Jovanovic, K., Parfitt, D. A., Schulkens, I., Chan, H. L., Schmidt, I., Beumer, W., Vorthoren, L., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.07.010 · Cited by 165
Genetics of age-related macular degeneration (AMD)
DeAngelis, M. M., Owen, L. A., Morrison, M. A., Morgan, D. J., Li, M., Shakoor, A., Vitale, A., Iyengar, S., Stambolian, D., Kim, I. K., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx228 · Cited by 164
Versatility of AAV vectors for retinal gene transfer
Surace, E. M., & Auricchio, A. (2007) · Vision Research · doi:10.1016/j.visres.2007.07.027 · Cited by 162
Gene therapy progress and prospects: the eye
Bainbridge, J. W., Tan, M. H., & Ali, R. R. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302812 · Cited by 162
RPE65: Role in the Visual Cycle, Human Retinal Disease, and Gene Therapy
Cai, X., Conley, S. M., & Naash, M. I. (2009) · Ophthalmic Genetics · doi:10.1080/13816810802626399 · Cited by 162 · cited 14×
“In fibroblasts from patients with LCA, the aberrant CEP290 junction was corrected, CEP290 protein levels were restored, and the ciliary phenotype was completely rescued after AON administration.”
BackgroundMethodInfluentialGeneration and characterization of chimeric recombinant AAV vectors
Hauck, B., Chen, L., & Xiao, W. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00012-1 · Cited by 160
Rhodopsin Signaling and Organization in Heterozygote Rhodopsin Knockout Mice
Liang, Y., Fotiadis, D., Maeda, T., Maeda, A., Modzelewska, A., Filipek, S., Saperstein, D. A., Engel, A., & Palczewski, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408362200 · Cited by 157 · cited 1×
“The first includes the use of specific allele inhibitors that promote degradation of the mutated mRNA and allow the expression of the normal allele, sufficient to maintain the function of the photoreceptor cells [110].”
BackgroundInhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1
Bainbridge, J. W., Mistry, A., de Alwis, M., Paleolog, E. M., Baker, A. H., Thrasher, A. J., & Ali, R. R. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301680 · Cited by 156
SHI, F., WASUNGU, L., NOMDEN, A., STUART, M. C. A., POLUSHKIN, E., ENGBERTS, J. B. F. N., & HOEKSTRA, D. (2002) · Biochemical Journal · doi:10.1042/bj20020590 · Cited by 149
Grayson, C. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.12.1873 · Cited by 148
Lü, J., Sista, P. R., Giguel, F. F., Greenberg, M., & Kuritzkes, D. R. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4628-4637.2004 · Cited by 144
Second–generation adenovirus vectors
Wang, Q. K., & Finer, M. H. (1996) · Nature Medicine · doi:10.1038/nm0696-714 · Cited by 143
The privileged immunity of immune privileged organs: the case of the eye
Benhar, I., London, A., & Schwartz, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00296 · Cited by 142
AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa
Smith, A. J., Schlichtenbrede, F. C., Tschernutter, M., Bainbridge, J. W., Thrasher, A. J., & Ali, R. R. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00144-8 · Cited by 140
Tschernutter, M., Schlichtenbrede, F. C., Howe, S. J., Balaggan, K. S., Munro, P., Bainbridge, J. W., Thrasher, A. J., Smith, A. J., & Ali, R. R. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302460 · Cited by 140
Auricchio, A., Behling, K. C., Maguire, A. M., O'Connor, E. E., Bennett, J., Wilson, J. M., & Tolentino, M. J. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0702 · Cited by 137
High-Capacity “Gutless” Adenoviral Vectors
Schiedner, G., Clemens, P. R., Volpers, C., & Kochanek, S. (2002) · Elsevier eBooks · doi:10.1016/b978-012199504-1/50016-x · Cited by 137
Combinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus
Perabo, L., Endell, J., King, S., Lux, K., Goldnau, D., Hallek, M., & Büning, H. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.849 · Cited by 136
Unravelling the genetics of inherited retinal dystrophies: Past, present and future
Broadgate, S., Yu, J., Downes, S. M., & Halford, S. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.03.003 · Cited by 136
O’Neal, W. K., Zhou, H., Morral, N., Aguilar-Córdova, E., Pestaner, J. P., Langston, C., Mull, B. B., Wang, Y., Beaudet, A. L., & Lee, B. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.11-1587 · Cited by 135
Slijkerman, R. W. N., Song, F., Astuti, G., Huynen, M. A., van Wijk, E., Stieger, K., & Collin, R. W. J. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.04.004 · Cited by 135
Vitreous Is a Barrier in Nonviral Gene Transfer by Cationic Lipids and Polymers
Pitkänen, L., Ruponen, M., Nieminen, J., & Urtti, A. (2003) · Pharmaceutical Research · doi:10.1023/a:1023238530504 · Cited by 134
Batten, M. L., Imanishi, Y., Tu, D. C., Doan, T., Zhu, L., Pang, J., Glushakova, L., Moise, A. R., Baehr, W., Van Gelder, R. N., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020333 · Cited by 134 · cited 1×
“Better results have been obtained in disorders in which genetic defects originate in the RPE (such as RPE65- and MERTK-mediated dystrophies) [54,105,106].”
Novel Integrase-Defective Lentiviral Episomal Vectors for Gene Transfer
Vargas, J., Gusella, G. L., Najfeld, V., Klotman, M. E., & Cara, A. (2004) · Human Gene Therapy · doi:10.1089/104303404322959515 · Cited by 133
Pawlyk, B. S., Smith, A. J., Buch, P. K., Adamian, M., Hong, D.-H., Sandberg, M. A., Ali, R. R., & Li, T. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0371 · Cited by 126
Deshpande, M. C., Davies, M. C., Garnett, M. C., Williams, P. M., Armitage, D., Bailey, L., Vamvakaki, M., Armes, S. P., & Stolnik, S. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.019 · Cited by 121
Drug and Gene Delivery to the Back of the Eye: From Bench to Bedside
Rowe-Rendleman, C. L., Durazo, S. A., Kompella, U. B., Rittenhouse, K. D., Di Polo, A., Weiner, A. L., Grossniklaus, H. E., Naash, M. I., Lewin, A. S., Horsager, A., et al. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13707 · Cited by 120 · cited 1×
“Additionally, in this case, the eye immune privilege [6] confers the possibility of supplying AON molecules directly to the retina by intravitreal or subretinal injections, with minimal toxic immunological side effects [140].”
BackgroundSaenz, D. T., Loewen, N., Peretz, M., Whitwam, T., Barraza, R., Howell, K. G., Holmes, J. M., Good, M., & Poeschla, E. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.2906-2920.2004 · Cited by 119
Tan, M. H., Smith, A. J., Pawlyk, B., Xu, X., Liu, X., Bainbridge, J. B., Basche, M., McIntosh, J., Tran, H. V., Nathwani, A., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp133 · Cited by 119
van Adel, B. A., Kostic, C., Déglon, N., Ball, A. K., & Arsenijevic, Y. (2003) · Human Gene Therapy · doi:10.1089/104303403321070801 · Cited by 115
Raisler, B. J., Berns, K. I., Grant, M. B., Beliaev, D., & Hauswirth, W. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122247299 · Cited by 113
Garanto, A., Chung, D. C., Duijkers, L., Corral-Serrano, J. C., Messchaert, M., Xiao, R., Bennett, J., Vandenberghe, L. H., & Collin, R. W. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw118 · Cited by 110
Retinal gene therapy: surgical vector delivery in the translation to clinical trials
Ochakovski, G. A., Bartz-Schmidt, K. U., & Fischer, M. D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00174 · Cited by 110
Current Developments in Gene Transfection Agents
Azzam, T., & Domb, A. J. (2004) · Current Drug Delivery · doi:10.2174/1567201043479902 · Cited by 105
Murray, S. F., Jazayeri, A., Matthes, M. T., Yasumura, D., Yang, H., Peralta, R., Watt, A., Freier, S., Hung, G., Adamson, P. S., et al. (2015) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-16400 · Cited by 105
Zhou, Y., Pernet, V., Hauswirth, W. W., & Di Polo, A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.004 · Cited by 103
Zallocchi, M., Binley, K., Lad, Y., Ellis, S., Widdowson, P., Iqball, S., Scripps, V., Kelleher, M., Loader, J., Miskin, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094272 · Cited by 102
Aberrant splicing of the CHM gene is a significant cause of choroideremia
Sankila, E., Tolvanen, R., van den Hurk, J. A. J. M., Cremers, F. P. M., & de la Chapelle, A. (1992) · Nature Genetics · doi:10.1038/ng0592-109 · Cited by 101
Thompson, D. A., Ali, R. R., Banin, E., Branham, K. E., Flannery, J. G., Gamm, D. M., Hauswirth, W. W., Heckenlively, J. R., Iannaccone, A., Jayasundera, K. T., et al. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-16049 · Cited by 101
Lai, C., Yu, M. J. T., Brankov, M., Barnett, N. L., Zhou, X., Redmond, T. M., Narfström, K. L., & Rakoczy, P. E. (2004) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-2-3 · Cited by 100
CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa
Wu, W.-H., Tsai, Y.-T., Justus, S., Lee, T.-T., Zhang, L., Lin, C.-S., Bassuk, A. G., Mahajan, V. B., & Tsang, S. H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.107 · Cited by 99
The gene for Stargardt disease, ABCA4, is a major retinal gene: a mini-review
Koenekoop, R. K. (2003) · Ophthalmic Genetics · doi:10.1076/opge.24.2.75.13996 · Cited by 97
Janssen, A., Min, S. H., Molday, L. L., Tanimoto, N., Seeliger, M. W., Hauswirth, W. W., Molday, R. S., & Weber, B. H. (2008) · Molecular Therapy · doi:10.1038/mt.2008.57 · Cited by 95
O’Neal, W. K., Zhou, H., Morral, N., Langston, C., Parks, R. J., Graham, F. L., Kochanek, S., & Beaudet, A. L. (2000) · Molecular Medicine · doi:10.1007/bf03402113 · Cited by 91
Gene transfer into retinal ganglion cells by in vivo electroporation: a new approach
Dezawa, M., Takano, M., Negishi, H., Mo, X., Oshitari, T., & Sawada, H. (2002) · Micron · doi:10.1016/s0968-4328(01)00002-6 · Cited by 91
Novel mutations in MERTK associated with childhood onset rod-cone dystrophy.
Mackay, D. S., Henderson, R., Sergouniotis, P. I., Li, Z., Moradi, P., Holder, G. E., Waseem, N. H., Bhattacharya, S. S., Aldahmesh, M. A., Alkuraya, F. S., et al. (2010) · PubMed Central · Cited by 90
Gene therapy for inherited retinal and optic nerve degenerations
Moore, N. A., Morral, N., Ciulla, T. A., & Bracha, P. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389886 · Cited by 89
Remmer, M. H., Rastogi, N., Ranka, M. P., & Ceisler, E. J. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000189 · Cited by 88
Sorrentino, F. S., Gallenga, C. E., Bonifazzi, C., & Perri, P. (2016) · Eye · doi:10.1038/eye.2016.197 · Cited by 88
Lai, L.-J., Xiao, X., & Wu, J. H. (2007) · Journal of Biomedical Science · doi:10.1007/s11373-007-9153-7 · Cited by 87
Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa.
Drenser, K. A., Timmers, A. M., Hauswirth, W. W., & Lewin, A. S. (1998) · PubMed · Cited by 86
Bush, R. A., Zeng, Y., Colosi, P., Kjellstrom, S., Hiriyanna, S., Vijayasarathy, C., Santos, M., Li, J., Wu, Z., & Sieving, P. A. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.142 · Cited by 86
Cai, Y., Cheng, T., Yao, Y., Li, X., Ma, Y., Li, L., Zhao, H., Bao, J., Zhang, M., Qiu, Z., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav3335 · Cited by 86
Gorbatyuk, M. S., Justilien, V., Liu, J., Hauswirth, W. W., & Lewin, A. S. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2006.08.014 · Cited by 85
Kiang, A.-S., Palfi, A., Ader, M., Kenna, P. F., Millington-Ward, S., Clark, G., Kennan, A., O'Reilly, M., Tam, L. C. T., Aherne, A., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.028 · Cited by 84
The Spectrum of CHM Gene Mutations in Choroideremia and Their Relationship to Clinical Phenotype
Simunovic, M. P., Jolly, J. K., Xue, K., Edwards, T. L., Groppe, M., Downes, S. M., & MacLaren, R. E. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20230 · Cited by 83
Clinical and Genetic Features of Choroideremia in Childhood
Khan, K. N., Islam, F., Moore, A. T., & Michaelides, M. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.06.051 · Cited by 82
Custom Adeno-Associated Virus Capsids: The Next Generation of Recombinant Vectors with Novel Tropism
Muzyczka, N., & Warrington, K. H. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.408 · Cited by 80
Altering AAV tropism with mosaic viral capsids
Gigout, L., Rebollo, P., Clement, N., Warrington, K. H., Muzyczka, N., Linden, R. M., & Weber, T. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.005 · Cited by 79
Mao, H., Gorbatyuk, M. S., Rossmiller, B., Hauswirth, W. W., & Lewin, A. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.213 · Cited by 79
AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models
Vasireddy, V., Mills, J. A., Gaddameedi, R., Basner-Tschakarjan, E., Kohnke, M., Black, A. D., Alexandrov, K., Zhou, S., Maguire, A. M., Chung, D. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061396 · Cited by 79
Moosajee, M., Tracey-White, D., Smart, M., Weetall, M., Torriano, S., Kalatzis, V., da Cruz, L., Coffey, P., Webster, A. R., & Welch, E. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw184 · Cited by 77
Amalfitano, A., Begy, C. R., & Chamberlain, J. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3352 · Cited by 76
Gene therapy for Stargardt disease associated with ABCA4 gene
Han, Z., Conley, S. M., & Naash, M. I. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_90 · Cited by 74
Adeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina
Trapani, I. (2019) · Genes · doi:10.3390/genes10040287 · Cited by 73 · cited 1×
“Therefore, in recent years, considerable effort has been made to identify strategies to increase the transfer capacity of AAV vectors [62].”
BackgroundDudley, R. W. R., Lu, Y., Gilbert, R., Matecki, S., Nalbantoglu, J., Petrof, B. J., & Karpati, G. (2004) · Human Gene Therapy · doi:10.1089/104303404772679959 · Cited by 72
Cashman, S. M., Sadowski, S. L., Morris, D. J., Frederick, J., & Kumar-Singh, R. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0806 · Cited by 68
Bowles, D. E., Rabinowitz, J. E., & Samulski, R. J. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.423-432.2003 · Cited by 67
Correlation of Regenerable Opsin with Rod ERG Signal in Rpe65−/−Mice during Development and Aging
Rohrer, B., Goletz, P., Znoiko, S., Ablonczy, Z., Ma, J.-X., Redmond, T. M., & Crouch, R. K. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0567 · Cited by 65
Li, X., Li, W., Dai, X., Kong, F., Zheng, Q., Zhou, X., Lü, F., Chang, B., Rohrer, B., Hauswirth, W. W., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6138 · Cited by 64
Improved Vascular Gene Transfer With a Helper-Dependent Adenoviral Vector
Wen, S., Graf, S., Massey, P. G., & Dichek, D. A. (2004) · Circulation · doi:10.1161/01.cir.0000141574.78032.a9 · Cited by 64
Novel approaches for retinal drug delivery
Kurz, D. E., & Ciulla, T. A. (2002) · Ophthalmology Clinics of North America · doi:10.1016/s0896-1549(02)00034-2 · Cited by 61
Identification and Characterization of Novel Adeno-Associated Virus Isolates in ATCC Virus Stocks
Schmidt, M., Grot, E., Cervenka, P., Wainer, S., Buck, C., & Chiorini, J. A. (2006) · Journal of Virology · doi:10.1128/jvi.80.10.5082-5085.2006 · Cited by 60
Nomura, S., Merched, A. J., Nour, E. A., Dieker, C., Oka, K., & Chan, L. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302310 · Cited by 59
MacDonald, I. M., Sereda, C., McTaggart, K., & Mah, D. (2004) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.4.4.478 · Cited by 59
Broderick, C. A., Smith, A. J., Balaggan, K. S., Georgarias, A., Buch, P. K., Trittibach, P. C., Barker, S. E., Sarra, G.-M., Thrasher, A. J., Dick, A. D., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.018 · Cited by 58
PREVEC, L., Bs, C., Ke, L., Mm, B., Fl, G., & Rosenthal, K. L. (1991) · PubMed · Cited by 58
Tyrosine-Mutant AAV8 Delivery of Human MERTK Provides Long-Term Retinal Preservation in RCS Rats
Deng, W.-T., Dinculescu, A., Li, Q., Boye, S. L., Li, J., Gorbatyuk, M. S., Pang, J., Chiodo, V. A., Matthes, M. T., Yasumura, D., et al. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-8831 · Cited by 55
Beverly, M. B., Hartsough, K., Machemer, L., Pavco, P. A., & Lockridge, J. A. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.03.008 · Cited by 54
Nonviral ocular gene therapy: assessment and future directions.
Conley, S. M., Cai, X., & Naash, M. I. (2008) · PubMed · Cited by 52
Moosajee, M., Tulloch, M., Baron, R., Gregory, C. Y., Pereira‐Leal, J. B., & Seabra, M. C. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2755 · Cited by 49
Gorbatyuk, M. S., Pang, J., Thomas, J., Hauswirth, W. W., & Lewin, A. S. (2005) · PubMed · Cited by 49
RNAi-based suppression and replacement of rds-peripherin in retinal organotypic culture
Palfi, A., Ader, M., Kiang, A.-S., Millington-Ward, S., Clark, G., O'Reilly, M., McMahon, H. P., Kenna, P. F., Humphries, P., & Farrar, G. J. (2006) · Human Mutation · doi:10.1002/humu.20287 · Cited by 48
Voretigene Neparvovec: An Emerging Gene Therapy for the Treatment of Inherited Blindness
Patel, U. A., Boucher, M., de Léséleuc, L., & Visintini, S. M. (2016) · Europe PMC (PubMed Central) · Cited by 48
Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference
Cashman, S. M., Binkley, E. A., & Kumar‐Singh, R. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302512 · Cited by 47
In Vitro Gene Delivery in Retinal Pigment Epithelium Cells by Plasmid DNA-Wrapped Gold Nanoparticles
Trigueros, S., B. Domènech, E., Toulis, V., & Marfany, G. (2019) · Genes · doi:10.3390/genes10040289 · Cited by 45
Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa.
O’Neill, B., Millington‐Ward, S., O’Reilly, M., Tuohy, G., Kiang, A. –., Kenna, P. F., Humphries, P., & Farrar, G. J. (2000) · PubMed · Cited by 44
Generation of Adenovirus Vectors Devoid of All Viral Genes by Recombination Between Inverted Repeats
Stecher, H., Carlson, C. A., Shayakhmetov, D. M., & Lieber, A. (2003) · Viral Vectors for Gene Therapy · doi:10.1385/1-59259-304-6:135 · Cited by 44
Gene Therapy for MERTK-Associated Retinal Degenerations
LaVail, M. M., Yasumura, D., Matthes, M. T., Yang, H., Hauswirth, W. W., Deng, W.-T., & Vollrath, D. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-17121-0_65 · Cited by 43
NILSSON, S. E. G., Wrigstad, A., & Narfström, K. (1992) · Experimental Eye Research · doi:10.1016/s0014-4835(05)80218-0 · Cited by 42
Tessitore, A., Parisi, F., Denti, M. A., Allocca, M., Di Vicino, U., Domenici, L., Bozzoni, I., & Auricchio, A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.07.008 · Cited by 41
Gene Therapy for Color Blindness.
Hassall, M., Barnard, A. R., & MacLaren, R. E. (2017) · PubMed Central · Cited by 40
Generation of Adenovirus Vectors Devoid of All Viral Genes by Recombination between Inverted Repeats
Steinwaerder, D. S., Carlson, C. A., & Lieber, A. (1999) · Journal of Virology · doi:10.1128/jvi.73.11.9303-9313.1999 · Cited by 40
Homozygous Mutation in MERTK Causes Severe Autosomal Recessive Retinitis Pigmentosa
Ksantini, M., Lafont, E., Bocquet, B., Meunier, I., & Hamel, C. P. (2012) · European Journal of Ophthalmology · doi:10.5301/ejo.5000096 · Cited by 39
XIAP-mediated neuroprotection in retinal ischemia
Renwick, J., Narang, M. A., Coupland, S. G., Xuan, J. Y., Baker, A. N., Brousseau, J., Petrin, D., Munger, R., Leonard, B. C., Hauswirth, W. W., et al. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302683 · Cited by 38
Correction of Monogenic and Common Retinal Disorders with Gene Therapy
Sengillo, J., Justus, S., Cabral, T., & Tsang, S. (2017) · Genes · doi:10.3390/genes8020053 · Cited by 37
Marangoni, D., Bush, R. A., Zeng, Y., Wei, L. L., Ziccardi, L., Vijayasarathy, C., Bartoe, J. T., Palyada, K., Santos, M., Hiriyanna, S., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.11 · Cited by 36
Self-citationNon-viral siRNA delivery into the mouse retina in vivo
Turchinovich, A. A., Zoidl, G., & Dermietzel, R. (2010) · BMC Ophthalmology · doi:10.1186/1471-2415-10-25 · Cited by 35
Sullivan, J. M., Pietras, K. M., Shin, B. J., & Misasi, J. (2002) · PubMed · Cited by 35
Lymphatic vessels of the eye – old questions – new insights
Grüntzig, J. W., & Hollmann, F. (2018) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2018.08.004 · Cited by 35
Unmet Needs in Ophthalmology: A European Vision Institute-Consensus Roadmap 2019–2025
Cursiefen, C., Cordeiro, M. F., Cunha-Vaz, J. G., Wheeler‐Schilling, T. H., Scholl, H. P. N., & on behalf of the EVI Steering Board (2019) · Ophthalmic Research · doi:10.1159/000501374 · Cited by 35
Intravitreal Injection of Splice-switching Oligonucleotides to Manipulate Splicing in Retinal Cells
Gérard, X., Perrault, I., Munnich, A., Kaplan, J., & Rozet, J.-M. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.24 · Cited by 34
Gene Therapy for Genetic and Acquired Retinal Diseases
Chaum, E., & Hatton, M. P. (2002) · Survey of Ophthalmology · doi:10.1016/s0039-6257(02)00336-3 · Cited by 33
The Blunt End: Surgical Challenges of Gene Therapy for Inherited Retinal Diseases
Davis, J. L. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.08.038 · Cited by 30
Petrs-Silva, H., Yasumura, D., Matthes, M. T., LaVail, M. M., Lewin, A. S., & Hauswirth, W. W. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-0631-0_29 · Cited by 26
Gene Delivery to the Retina Using Lentiviral Vectors
Greenberg, K. P., Lee, E. S., Schaffer, D. V., & Flannery, J. G. (2007) · Springer eBooks · doi:10.1007/0-387-32442-9_36 · Cited by 24
Hernán, I., Gamundi, M. J., Planas‐Rigol, E., Borràs, E., Maseras, M., & Carballo, M. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6933 · Cited by 22
Cashman, S. M., Gracias, J., Adhi, M., & Kumar‐Singh, R. (2015) · The Journal of Gene Medicine · doi:10.1002/jgm.2865 · Cited by 21
Lai, L. J., Lin, K. K., Foulks, G. N., Ma, L., Xiao, X., & Chen, K. H. (2005) · Current Eye Research · doi:10.1080/02713680590927515 · Cited by 21
Matet, A., Kostic, C., Bemelmans, A.-P., Moulin, A., Rosolen, S. G., Martin, S., Mavilio, F., Amirjanians, V., Stieger, K., Lorenz, B., et al. (2017) · Translational Research · doi:10.1016/j.trsl.2017.06.012 · Cited by 20
Challenges in non-viral ocular gene transfer
Peeters, L., Sanders, N. N., Demeester, J., & Smedt, S. C. D. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350047 · Cited by 18
Folding and catalysis by the hairpin ribozyme
Lilley, D. M. J. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00544-x · Cited by 15
A Practical Approach to Retinal Dystrophies
Tsui, I., Song, B. J., Lin, C., & Tsang, S. H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-95046-4_51 · Cited by 11
Molecular biology tools for the study and therapy of PDE6β mutations
Bitoque, D. B., & Silva, G. A. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.07.030 · Cited by 4
Research works printed but not linked: 1
- Duane, T.D., Tasman, W., and Jaeger, A.E. (1996). Molecular physiology and pathology of the retina. Duane’s Clinical Opthalmology, Lippincott-Raven.
Cited by
Schneider, N., Sundaresan, Y., Gopalakrishnan, P., Beryozkin, A., Hanany, M., Levanon, E. Y., Banin, E., Ben-Aroya, S., & Sharon, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101029 · Cited by 224
Maya-Vetencourt, J. F., Manfredi, G., Mete, M., Colombo, E., Bramini, M., Di Marco, S., Shmal, D., Mantero, G., Dipalo, M., Rocchi, A., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0696-3 · Cited by 211
Barani, M., Nematollahi, M. H., Zaboli, M., Mirzaei, M., Torkzadeh‐Mahani, M., Pardakhty, A., & Asadikaram, G. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.09.026 · Cited by 98
The Role of Inflammation in Retinal Neurodegeneration and Degenerative Diseases
Kaur, G., & Singh, N. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010386 · Cited by 101
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“In most clinical retinal gene therapy studies, the vector of choice is the rAAV gene expression vector [14].”
Background
Metadata
- Authors
- Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M.
- Affiliations
- Fondazione G.B. Bietti (IT)
- Istituto Superiore di Sanità (IT)
- National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
- Corresponding author
- Ziccardi, Lucia
- Cordeddu, Viviana
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-11-14
- Volume
- 20
- Issue
- 22
- Pages
- 5722
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6888000
- OpenAlex
- W2987842697
- Cited by
- 107
- References
- 188
- Citations by year
- 2026: 5 · 2025: 16 · 2024: 11 · 2023: 13 · 2022: 16 · 2021: 25 · 2020: 18 · 2019: 1
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi del Molise (submittedVersion)
- Funders
- Ministero della Salute
- Fondazione Roma
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, inherited retinal disease, Leber congenital amaurosis, Luxturna, disease-associated genes, molecular diagnosis, genome sequencing, clinical trials, translational research, retinal degeneration
- MeSH terms
- Gene Editing, Animals, Disease Models, Animal, Genetic Vectors, Humans, Genetic Therapy, Treatment Outcome, Gene Transfer Techniques, Transgenes, Genetic Predisposition to Disease, Retinal Dystrophies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.